Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 21792748)

1.

Advances in rheumatoid arthritis animal models.

Moudgil KD, Kim P, Brahn E.

Curr Rheumatol Rep. 2011 Oct;13(5):456-63. doi: 10.1007/s11926-011-0200-z.

2.

[Bone and cartilage destruction in rheumatoid arthritis].

Komatsu N, Takayanagi H.

Clin Calcium. 2012 Feb;22(2):179-85. doi: CliCa1202179185. Review. Japanese.

PMID:
22298070
3.

Rheumatoid arthritis: regulation of synovial inflammation.

Sweeney SE, Firestein GS.

Int J Biochem Cell Biol. 2004 Mar;36(3):372-8. Review.

PMID:
14687914
4.

Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Esensten JH, Wofsy D, Bluestone JA.

Nat Rev Rheumatol. 2009 Oct;5(10):560-5. doi: 10.1038/nrrheum.2009.183. Review.

5.

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, HeinegÄrd D, van den Berg WB.

Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.

6.

Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.

Lu Y, Xiao J, Wu ZW, Wang ZM, Hu J, Fu HZ, Chen YY, Qian RQ.

Phytomedicine. 2012 Jul 15;19(10):882-9. doi: 10.1016/j.phymed.2012.04.010. Epub 2012 Jun 4.

PMID:
22673798
7.
8.

Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.

Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G.

Arthritis Rheumatol. 2014 Nov;66(11):2989-3000. doi: 10.1002/art.38624.

PMID:
24623505
9.

Effector T cells in rheumatoid arthritis: lessons from animal models.

Alzabin S, Williams RO.

FEBS Lett. 2011 Dec 1;585(23):3649-59. doi: 10.1016/j.febslet.2011.04.034. Epub 2011 Apr 19. Review.

10.

Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis.

Cho YG, Cho ML, Min SY, Kim HY.

Autoimmun Rev. 2007 Nov;7(1):65-70. Epub 2007 Aug 30. Review.

PMID:
17967728
11.

Mechanisms of bone and cartilage destruction in rheumatoid arthritis: lessons from the streptococcal cell wall arthritis model in LEW/N rats.

Wilder RL, Lafyatis R, Yocum DE, Case JP, Kumkumian GK, Remmers EF.

Clin Exp Rheumatol. 1989 Sep-Oct;7 Suppl 3:S123-7. Review.

PMID:
2691148
12.

Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis.

Flores-Borja F, Mauri C, Ehrenstein MR.

Eur J Immunol. 2008 Apr;38(4):934-7. doi: 10.1002/eji.200738107.

PMID:
18395847
13.

Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition.

Klareskog L, Rönnelid J, Holm G.

J Intern Med. 1995 Sep;238(3):191-206. Review.

PMID:
7673848
14.

Breaking old paradigms: Th17 cells in autoimmune arthritis.

Peck A, Mellins ED.

Clin Immunol. 2009 Sep;132(3):295-304. doi: 10.1016/j.clim.2009.03.522. Epub 2009 Apr 28. Review.

15.

A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis.

Miyata S, Ohkubo Y, Mutoh S.

Inflamm Res. 2005 Jan;54(1):1-9. Review.

PMID:
15723198
16.

Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis.

Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z.

Arthritis Res Ther. 2010;12(6):R210. doi: 10.1186/ar3187. Epub 2010 Nov 16.

17.

[Involvement of osteoclasts in cartilage and bone destruction in rheumatoid arthritis].

Hikita A, Tanaka S.

Nihon Rinsho. 2005 Jan;63 Suppl 1:84-6. Review. Japanese. No abstract available.

PMID:
15799323
18.

Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production.

Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, Koenders MI, van den Berg WB.

Arthritis Rheum. 2008 Dec;58(12):3753-64. doi: 10.1002/art.24127.

19.

Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis.

Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y, Sun T, Li S, Li D.

Int J Mol Med. 2014 Mar;33(3):711-21. doi: 10.3892/ijmm.2013.1611. Epub 2013 Dec 27.

PMID:
24378614
20.

A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Astry B, Harberts E, Moudgil KD.

J Interferon Cytokine Res. 2011 Dec;31(12):927-40. doi: 10.1089/jir.2011.0094. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk